Relugolix
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-RELUGOLIX |
|---|---|
| Type | Drug |
| Aliases | OrgovyxРелуголікс |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Drug Facts
| Class | GnRH antagonist (oral) |
|---|---|
| Mechanism | Oral GnRH-receptor antagonist — first oral ADT option. Rapid testosterone suppression; cardiovascular profile favorable vs LHRH agonists in HERO trial. |
| Typical dosing | 360 mg PO loading dose day 1, then 120 mg PO once daily. |
| Ukraine registered | False |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-04-27 |
Notes
Best CV safety profile of any ADT in HERO trial (54% relative MACE reduction vs leuprolide). UA-access major barrier; flagged for clinician review.
Used By
No reverse references found in the YAML corpus.